OncoMatch/Clinical Trials/NCT04150497
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Is NCT04150497 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including UCART22 and CLLS52 for b-cell acute lymphoblastic leukemia.
Treatment: UCART22 · CLLS52 — This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD22 expression
Prior therapy
Must have received: chemotherapy — standard
at least one standard chemotherapy regimen
Must have received: chemotherapy — salvage
at least one salvage regimen
Cannot have received: cellular therapy
Prior cellular therapy or investigational cellular or gene therapy within 90 days prior to enrollment
Cannot have received: gene therapy
Prior cellular therapy or investigational cellular or gene therapy within 90 days prior to enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Los Angeles (UCLA) - Medical Center · Los Angeles, California
- University of Colorado - Aurora Cancer Center · Aurora, Colorado
- Sarah Cannon - Colorado Blood Cancer Institute · Denver, Colorado
- University of Chicago · Chicago, Illinois
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify